NovAccess Global Inc. (XSNX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.46 Million USD | -80.36% |
| 2022 | -1.36 Million USD | 49.33% |
| 2021 | -2.69 Million USD | -225.61% |
| 2020 | -828.89 Thousand USD | -499.89% |
| 2019 | 207.28 Thousand USD | 202.46% |
| 2018 | -202.29 Thousand USD | -181.59% |
| 2017 | -71.84 Thousand USD | 65.44% |
| 2016 | -207.85 Thousand USD | 6.46% |
| 2015 | -222.22 Thousand USD | 48.6% |
| 2014 | -432.35 Thousand USD | 56.46% |
| 2013 | -992.93 Thousand USD | -22.6% |
| 2012 | -809.92 Thousand USD | 36.1% |
| 2011 | -1.26 Million USD | 31.52% |
| 2010 | -1.85 Million USD | 53.48% |
| 2009 | -3.97 Million USD | 6.65% |
| 2008 | -4.26 Million USD | -61.42% |
| 2007 | -2.64 Million USD | 21.6% |
| 2006 | -3.36 Million USD | -143.45% |
| 2005 | -1.38 Million USD | 9.45% |
| 2004 | -1.52 Million USD | -947.54% |
| 2003 | -145.84 Thousand USD | -208.36% |
| 2002 | -47.29 Thousand USD | -178.37% |
| 2001 | -16.99 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -232.56 Thousand USD | 9.7% |
| 2024 Q1 | -257.55 Thousand USD | 37.18% |
| 2024 Q3 | -936.33 Thousand USD | -35.6% |
| 2023 FY | -2.46 Million USD | -80.36% |
| 2023 Q1 | -517.12 Thousand USD | -76.21% |
| 2023 Q4 | -410.01 Thousand USD | 15.4% |
| 2023 Q3 | -484.64 Thousand USD | 54.06% |
| 2023 Q2 | -1.05 Million USD | -104.01% |
| 2022 Q4 | -293.46 Thousand USD | 9.68% |
| 2022 Q1 | -322.32 Thousand USD | 37.56% |
| 2022 Q2 | -974.18 Thousand USD | -202.23% |
| 2022 Q3 | -324.91 Thousand USD | 66.65% |
| 2022 FY | -1.36 Million USD | 49.33% |
| 2021 Q4 | -516.23 Thousand USD | -2.94% |
| 2021 Q1 | -1.39 Million USD | -1689.91% |
| 2021 Q3 | -501.49 Thousand USD | -78.26% |
| 2021 FY | -2.69 Million USD | -225.61% |
| 2021 Q2 | -281.32 Thousand USD | 79.9% |
| 2020 FY | -828.89 Thousand USD | -499.89% |
| 2020 Q3 | -489.87 Thousand USD | -563.87% |
| 2020 Q2 | 105.6 Thousand USD | 236.02% |
| 2020 Q1 | -77.63 Thousand USD | -167.6% |
| 2020 Q4 | -78.21 Thousand USD | 84.03% |
| 2019 FY | 207.28 Thousand USD | 202.46% |
| 2019 Q1 | -22.41 Thousand USD | 44.42% |
| 2019 Q2 | 132.83 Thousand USD | 692.65% |
| 2019 Q3 | -17.98 Thousand USD | -113.54% |
| 2019 Q4 | 114.84 Thousand USD | 738.52% |
| 2018 Q3 | -10.37 Thousand USD | 85.32% |
| 2018 Q4 | -40.32 Thousand USD | -288.85% |
| 2018 Q1 | -80.95 Thousand USD | -14.63% |
| 2018 Q2 | -70.64 Thousand USD | 12.74% |
| 2018 FY | -202.29 Thousand USD | -181.59% |
| 2017 Q4 | -70.62 Thousand USD | -142.67% |
| 2017 FY | -71.84 Thousand USD | 65.44% |
| 2017 Q3 | -29.1 Thousand USD | -148.35% |
| 2017 Q2 | 60.19 Thousand USD | 286.34% |
| 2017 Q1 | -32.3 Thousand USD | 46.25% |
| 2016 Q2 | 39.94 Thousand USD | 149.32% |
| 2016 Q1 | -80.99 Thousand USD | -634.35% |
| 2016 Q3 | -106.7 Thousand USD | -367.11% |
| 2016 Q4 | -60.09 Thousand USD | 43.68% |
| 2016 FY | -207.85 Thousand USD | 6.46% |
| 2015 FY | -222.22 Thousand USD | 48.6% |
| 2015 Q4 | -11.03 Thousand USD | 77.04% |
| 2015 Q3 | -48.03 Thousand USD | 31.35% |
| 2015 Q2 | -69.97 Thousand USD | 24.9% |
| 2015 Q1 | -93.17 Thousand USD | 50.94% |
| 2014 Q4 | -189.93 Thousand USD | -12259.48% |
| 2014 Q1 | -144.89 Thousand USD | 71.16% |
| 2014 FY | -432.35 Thousand USD | 56.46% |
| 2014 Q2 | -99.09 Thousand USD | 31.61% |
| 2014 Q3 | 1562.00 USD | 101.58% |
| 2013 FY | -992.93 Thousand USD | -22.6% |
| 2013 Q4 | -502.43 Thousand USD | -243.68% |
| 2013 Q3 | -146.19 Thousand USD | 21.25% |
| 2013 Q2 | -185.64 Thousand USD | -17.01% |
| 2013 Q1 | -158.65 Thousand USD | -40.06% |
| 2012 Q4 | -113.28 Thousand USD | 54.12% |
| 2012 FY | -809.92 Thousand USD | 36.1% |
| 2012 Q3 | -246.92 Thousand USD | -20.98% |
| 2012 Q2 | -204.09 Thousand USD | 16.91% |
| 2012 Q1 | -245.62 Thousand USD | 16.12% |
| 2011 Q3 | -295.16 Thousand USD | 2.65% |
| 2011 Q1 | -376.21 Thousand USD | -14.78% |
| 2011 Q2 | -303.21 Thousand USD | 19.4% |
| 2011 Q4 | -292.82 Thousand USD | 0.79% |
| 2011 FY | -1.26 Million USD | 31.52% |
| 2010 FY | -1.85 Million USD | 53.48% |
| 2010 Q2 | -564.51 Thousand USD | -6.16% |
| 2010 Q3 | -426.52 Thousand USD | 24.45% |
| 2010 Q1 | -531.75 Thousand USD | 42.58% |
| 2010 Q4 | -327.75 Thousand USD | 23.16% |
| 2009 Q2 | -967.39 Thousand USD | 21.7% |
| 2009 Q4 | -926.14 Thousand USD | -10.98% |
| 2009 Q3 | -834.5 Thousand USD | 13.74% |
| 2009 Q1 | -1.23 Million USD | -37.63% |
| 2009 FY | -3.97 Million USD | 6.65% |
| 2008 Q4 | -897.62 Thousand USD | -21.77% |
| 2008 Q3 | -737.17 Thousand USD | -2.13% |
| 2008 Q2 | -721.78 Thousand USD | 64.28% |
| 2008 Q1 | -2.02 Million USD | -110.93% |
| 2008 FY | -4.26 Million USD | -61.42% |
| 2007 Q2 | -498.89 Thousand USD | 19.08% |
| 2007 Q3 | -566.8 Thousand USD | -13.61% |
| 2007 Q4 | -958.05 Thousand USD | -69.03% |
| 2007 FY | -2.64 Million USD | 21.6% |
| 2007 Q1 | -616.49 Thousand USD | 48.47% |
| 2006 Q3 | -634.68 Thousand USD | -61.88% |
| 2006 Q4 | -1.19 Million USD | -88.52% |
| 2006 Q2 | -392.08 Thousand USD | 74.84% |
| 2006 Q1 | -1.55 Million USD | -113.18% |
| 2006 FY | -3.36 Million USD | -143.45% |
| 2005 Q1 | -164.79 Thousand USD | 87.32% |
| 2005 Q2 | -205.32 Thousand USD | -24.59% |
| 2005 Q3 | -282.27 Thousand USD | -37.48% |
| 2005 FY | -1.38 Million USD | 9.45% |
| 2005 Q4 | -731.01 Thousand USD | -158.97% |
| 2004 Q4 | -1.29 Million USD | -965.15% |
| 2004 Q3 | -122.02 Thousand USD | -89.34% |
| 2004 Q2 | -64.44 Thousand USD | -54.79% |
| 2004 Q1 | -41.63 Thousand USD | 68.31% |
| 2004 FY | -1.52 Million USD | -947.54% |
| 2003 Q4 | -131.4 Thousand USD | -896.51% |
| 2003 FY | -145.84 Thousand USD | -208.36% |
| 2003 Q2 | - USD | 100.0% |
| 2003 Q1 | -1259.00 USD | 95.35% |
| 2003 Q3 | -13.18 Thousand USD | 0.0% |
| 2002 Q4 | -27.08 Thousand USD | -4610.09% |
| 2002 Q1 | -2545.00 USD | 63.58% |
| 2002 Q3 | -575.00 USD | 96.64% |
| 2002 FY | -47.29 Thousand USD | -178.37% |
| 2002 Q2 | -17.09 Thousand USD | -571.67% |
| 2001 Q3 | -6733.00 USD | -442.11% |
| 2001 FY | -16.99 Thousand USD | 0.0% |
| 2001 Q4 | -6987.00 USD | -3.77% |
| 2001 Q2 | -1242.00 USD | 38.79% |
| 2001 Q1 | -2029.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -84.716% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 51.1% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 86.178% |
| Nascent Biotech, Inc. | -2.22 Million USD | -10.623% |
| Rebus Holdings, Inc. | -664 Thousand USD | -271.5% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 103.014% |
| Qrons Inc. | -643.67 Thousand USD | -283.229% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -533.201% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 95.556% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -493.715% |
| Skye Bioscience, Inc. | -13.67 Million USD | 81.957% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 96.564% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 150.19% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -842.497% |
| SQZ Biotechnologies Company | -75.82 Million USD | 96.747% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 13.462% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -60.591% |
| Mesoblast Limited | -84.14 Million USD | 97.069% |
| Marizyme, Inc. | -34.08 Million USD | 92.763% |
| Genus plc | 6.4 Million USD | 138.543% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 125.32% |
| Pharming Group N.V. | -4.87 Million USD | 49.447% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -24.178% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -164.85% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 70.458% |
| ContraFect Corporation | -56.88 Million USD | 95.664% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 45.842% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -75.947% |
| IMV Inc. | -38.67 Million USD | 93.621% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 10.327% |
| MultiCell Technologies, Inc. | -722.81 USD | -341173.64% |
| ONE Bio Corp. | 13.68 Million USD | 118.03% |
| Accustem Sciences Inc. | -3.74 Million USD | 34.157% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 95.818% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -410.651% |
| Q BioMed Inc. | -3.44 Million USD | 28.409% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 169.682% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 6.118% |
| Biomind Labs Inc. | -1 Million USD | -144.33% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 95.513% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 14.976% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 62.895% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -32.311% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -8135.71% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 84.456% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -27.639% |
| GB Sciences, Inc. | -1.42 Million USD | -73.653% |
| Alpha Cognition Inc. | -9.7 Million USD | 74.584% |
| HST Global, Inc. | -140.9 Thousand USD | -1650.63% |
| CSL Limited | 3.7 Billion USD | 100.067% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -119.286% |
| Halberd Corporation | -75.05 Thousand USD | -3186.822% |
| Enzolytics Inc. | -2.14 Million USD | -14.797% |
| Agentix Corp. | -1.37 Million USD | -79.825% |
| Resverlogix Corp. | -12.74 Million USD | 80.651% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 22.142% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.42% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -136.28% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 15.506% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -56.188% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 27.554% |
| AVAX Technologies, Inc. | 6.69 Million USD | 136.856% |
| Zenith Capital Corp. | -8.94 Million USD | 72.417% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.407% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -14059.692% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -0.466% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1338.264% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -23.045% |
| Kadimastem Ltd | -3.04 Million USD | 18.863% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -150.673% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -96.398% |
| BioStem Technologies, Inc. | -7.77 Million USD | 68.289% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1259.209% |
| LadRx Corporation | -3.82 Million USD | 35.486% |
| Cell Source, Inc. | -4.32 Million USD | 42.97% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -259.089% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -259.089% |
| Affymax, Inc. | -15.04 Million USD | 83.605% |
| Itoco Inc. | -919.14 Thousand USD | -168.377% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 41.8% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -120.443% |
| Mobile Lads Corp. | -554.55 Thousand USD | -344.822% |
| CytoDyn Inc. | -18.05 Million USD | 86.34% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -9700.397% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1020.857% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -336.809% |
| SYBLEU INC | -149.18 Thousand USD | -1553.546% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -35.811% |
| International Stem Cell Corporation | -663 Thousand USD | -272.06% |
| Bioxytran, Inc. | -3.82 Million USD | 35.428% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -4586.094% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -12027.63% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 93.198% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -52.457% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -235.233% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 20.708% |
| Neutra Corp. | -229.48 Thousand USD | -974.907% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 85.936% |
| PureTech Health plc | -146.19 Million USD | 98.313% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 88.522% |
| IXICO plc | -1.43 Million USD | -71.66% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 74.009% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.975% |
| CSL Limited | 3.81 Billion USD | 100.065% |
| Cellectis S.A. | -108.85 Million USD | 97.734% |